Abstract: The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

Abstract: The present invention provides a method of determining the absolute amount of a target polypeptide in a sample, said method comprising the following steps: (a) adding (aa) a fusion polypeptide to said sample, said fusion polypeptide comprising (i) at least one tag sequence and (ii) a subsequence of the target polypeptide; and (ab) a known absolute amount of a tag polypeptide comprising or consisting of said tag sequence according to (aa) to said sample, wherein said fusion polypeptide on the one hand is mass-altered as compared to said target polypeptide and said tag polypeptide on the other hand, for example, said fusion polypeptide on the one hand and said target polypeptide and said tag polypeptide on the other hand are differently isotope labeled; (b) performing proteolytic digestion of the mixture obtained in step (a); (c) subjecting the result of proteolytic digestion of step (b), optionally after chromatography, to mass spectrometric analysis; and (d) determining the absolute amount of said target poly

Abstract: A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

Abstract: The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.

Abstract: The present invention relates to an affinity ligand capable of selective interaction with an epitope sequence consisting of 47 amino acids or less and comprising the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2. Further, it relates to a polypeptide consisting of the epitope sequence and to uses of the affinity ligand and the polypeptide.

Abstract: The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.

Abstract: A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

Abstract: The present disclosure provides a method for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of PODXL protein in at least part of a sample earlier obtained from the subject, and determining a sample value corresponding to the evaluated amount; b) comparing said sample value from step a) with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to said second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to said first group. Related uses, means and a method of treatment are also provided.

Abstract: The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.

Abstract: In the present disclosure, there is provided a method for improving the immunodetectability of at least one protein in an optionally diluted sample of blood, serum or plasma, comprising a step of heating the sample to a temperature of 64-85° C. prior to a contact between the sample and at least one affinity ligand for detection and/or quantification of the at least one protein.

Abstract: There is provided a method for determining whether a mammalian subject having an ovarian cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined refer-ence value; and if said sample value is higher than said ref-erence value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the sub-ject belongs to the second group. Related peptides, affinity ligands, uses and further methods are also provided.

Abstract: The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

Abstract: The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.

Abstract: The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.

Abstract: The present invention provides methods, uses and means for breast cancer prognostics and treatment prediction. Provided methods comprises the steps of: providing a sample earlier obtained from a breast cancer subject; evaluating the amount of ANLN protein present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the sample value with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is not likely to benefit from an endocrine treatment or that a prognosis for said subject is worse than a reference prognosis associated with the reference value.

Abstract: The present invention relates to an affinity ligand capable of selective interaction with an epitope sequence consisting of 47 amino acids or less and comprising the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2. Further, it relates to a polypeptide consisting of the epitope sequence and to uses of the affinity ligand and the polypeptide.

Abstract: The present invention relates to an affinity ligand capable of selective interaction with a subset consisting of 37 consecutive amino acid residues or less from extracellular domains 2 and 3 of HER2, wherein the subset comprises the amino acid sequence LQVF and/or ESFDGD1 and to polypeptides consisting of such subsets.

Abstract: The present invention provides a method for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment, comprising the steps of: providing a sample earlier obtained from said subject; evaluating the amount of HMGCR protein or HMGCR mRNA present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the sample value obtained in step b) with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment. Further, a corresponding method of treatment is provided as well as further methods uses and means which may be employed in connection with breast cancer treatment or treatment prediction.

Abstract: The present invention provides new methods, uses and means for breast cancer prognostics. The provided method for establishing a prognosis for a mammalian subject having a breast cancer, comprises the steps of: obtaining a hormone receptor status of the subject; obtaining an HMGCR protein value of the subject; and correlating the hormone receptor status and the HMGCR protein of the subject to a prognosis for the subject.

Abstract: The present invention provides means, such as a method, for determining whether a prognosis for a mammalian subject having a breast cancer is better than a reference prognosis. The method comprises the steps of: providing a sample earlier obtained from the subject; evaluating the amount of RBM3 protein present in at least part of said sample, and determining a sample value corresponding to said evaluated amount; comparing the sample value obtained with a reference value associated with said reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said subject is better than said reference prognosis.